Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 15/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629026 | 1.00 | ACLY (0.48) | ACLYALDH1A1CA1CA2MMP2 | |
| SCHEMBL4627858 | 0.88 | ALDH1A1 (0.47) | ACLYALDH1A1MMP2MMP9MMP1 | |
| SCHEMBL4629234 | 0.88 | ALDH1A1 (0.47) | ACLYALDH1A1MMP2MMP9MMP1 | |
| SCHEMBL4629891 | 0.88 | ALDH1A1 (0.47) | ACLYALDH1A1MMP2MMP9MMP1 | |
| SCHEMBL4629590 | 0.88 | ALDH1A1 (0.47) | ACLYALDH1A1MMP2MMP9MMP1 | |
| SCHEMBL4629060 | 0.85 | ALDH1A1 (0.48) | ACLYALDH1A1MMP2MMP9MMP1 | |
| SCHEMBL4629244 | 0.85 | ALDH1A1 (0.48) | ACLYALDH1A1MMP2MMP9MMP1 | |
| SCHEMBL7228300 | 0.80 | MMP2 (0.49) | ALDH1A1MMP2MMP9MMP1MMP3 | |
| SCHEMBL7237508 | 0.80 | MMP2 (0.49) | ALDH1A1MMP2MMP9MMP1MMP3 | |
| SCHEMBL7228302 | 0.80 | MMP2 (0.49) | ALDH1A1MMP2MMP9MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981845-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2008-10-22 | — | — | EP | claimed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | claimed |
| WO-2007092558-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2007-08-16 | — | — | WO | claimed |
| EP-1981845-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | disclosed |
| WO-2007092558-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | HCCS, HAVCR2, SULT2A1 | ACLY 2581/4885ALDH1A1 907/4885CA1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.